The life expectancy of patients with metabolic syndrome after weight loss: study protocol for a randomized clinical trial (LIFEXPE-RT)

Oral Ospanov,Farida Bekmurzinova,Galymzhan Yeleuov,Irina Kadyrova

doi:10.1186/s13063-019-3304-9

Oral Ospanov, Farida Bekmurzinova + Show 2 more

Open Access

https://doi.org/10.1186/s13063-019-3304-9

Copy DOI

Journal: Trials	Publication Date: Apr 8, 2019
Citations: 6	License type: open-access

Affiliation: Polytechnic University of Bari, Astana Medical University

Abstract

BackgroundTo date, surgeons and physicians have found positive results treating metabolic syndrome with surgical and non-surgical weight loss therapies. The purpose of this study was to evaluate changes in telomere length in patients with metabolic syndrome after weight loss.Methods/designThis study is a three-arm randomized controlled trial. The first group is composed of patients who have undergone stapleless bypass surgery (one anastomosis gastric bypass with an obstructive stapleless pouch and anastomosis (LOAGB-OSPAN)). The second group of patients underwent standard gastric bypass surgery (laparoscopic mini-gastric bypass-one anastomosis gastric bypass (LMGB-OAGB). The patients in the third group received non-surgical weight loss therapy, including a hypocaloric diet with energy restriction (− 500 kcal/day).The aim is to compare changes—telomere length, body mass index, comorbidities, and quality of life—in patients with metabolic syndrome after weight loss.DiscussionTo the best of our knowledge, this is the first randomized study to simultaneously compare the effects of surgical and non-surgical weight loss on changes in telomere length. It could provide a solution to the growing problem of metabolic syndrome. Normalization of the body mass index results in improvements in the health of patients with metabolic syndrome.Trial registrationClinicalTrials.gov, NCT03667469. Registered on 11 September 2018.

Highlights

To date, surgeons and physicians have found positive results treating metabolic syndrome with surgical and non-surgical weight loss therapies
Study aim The aim of this study was to evaluate the changes in telomere length in patients with Metabolic syndrome (MetS) after weight loss induced by stapleless laparoscopic anastomosis gastric bypass–obstructive stapleless pouch and anastomosis (LOAGB-OSPAN), laparoscopic mini-gastric bypass– one anastomosis gastric bypass (LMGB-One anastomosis gastric bypass (OAGB)), and non-surgical weight loss therapy with energy restriction (− 500 kcal/day)
At present, the results of scientific research have been published indicating that normalization of the Body mass index (BMI) improves the health of patients with MetS [13]

Summary

Introduction

Surgeons and physicians have found positive results treating metabolic syndrome with surgical and non-surgical weight loss therapies. Metabolic syndrome (MetS), which is the result of abdominal obesity, is a complex combination of symptoms that are risk factors for cardiovascular disease and manifestations of type 2 diabetes or prediabetes, non-alcoholic. When hyperglycemia is inadequately controlled by lifestyle and optimal medical therapy. Surgery should be considered for patients with type 2 diabetes and BMI 30.0–34.9 kg/m2 if hyperglycemia is inadequately controlled despite optimal treatment with either oral or injectable medications. These BMI thresholds should be reduced by 2.5 kg/m2 for Asian patients [3].

Objectives

Methods

Findings

Conclusion